7,592 reports of this reaction
2.5% of all RANITIDINE reports
#8 most reported adverse reaction
HEPATIC CANCER is the #8 most commonly reported adverse reaction for RANITIDINE, manufactured by Ajanta Pharma USA Inc.. There are 7,592 FDA adverse event reports linking RANITIDINE to HEPATIC CANCER. This represents approximately 2.5% of all 308,223 adverse event reports for this drug.
RANITIDINE has an overall safety score of 95 out of 100. Patients taking RANITIDINE who experience hepatic cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATIC CANCER is a less commonly reported adverse event for RANITIDINE, but still significant enough to appear in the safety profile.
In addition to hepatic cancer, the following adverse reactions have been reported for RANITIDINE:
The following drugs have also been linked to hepatic cancer in FDA adverse event reports:
HEPATIC CANCER has been reported as an adverse event in 7,592 FDA reports for RANITIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATIC CANCER accounts for approximately 2.5% of all adverse event reports for RANITIDINE, making it a notable side effect.
If you experience hepatic cancer while taking RANITIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.